Literature DB >> 24270347

Cancer immunosurveillance and immunoediting by natural killer cells.

Emilie Gross1, John B Sunwoo, Jack D Bui.   

Abstract

Cancer immunosurveillance eradicates certain neoplasms, but the selective pressure exerted by this active surveillance leads to the emergence of immune evasive tumor clones in a process called cancer immunoediting. Natural killer (NK) cells are potent effectors of cancer immunoediting and can destroy tumors directly via exocytosis of cytotoxic granules or indirectly by producing interferon γ to activate M1 and TH1 immune responses. This review gathers current knowledge of NK immunosurveillance of primary tumors induced in mice and highlights the importance of NK immunosurveillance for human cancers. Evidence of NK immunoediting, as revealed by studies using NK-deficient models, demonstrates how exposure to NK cells engenders modification of cancer immunogenicity to permit survival and progression of the tumor clone in an immunocompetent environment.

Entities:  

Mesh:

Year:  2013        PMID: 24270347     DOI: 10.1097/PPO.0000000000000005

Source DB:  PubMed          Journal:  Cancer J        ISSN: 1528-9117            Impact factor:   3.360


  27 in total

Review 1.  An essential role for the immune system in the mechanism of tumor regression following targeted oncogene inactivation.

Authors:  Stephanie C Casey; Yulin Li; Dean W Felsher
Journal:  Immunol Res       Date:  2014-05       Impact factor: 2.829

2.  Combination Cancer Therapy Using Chimeric Antigen Receptor-Engineered Natural Killer Cells as Drug Carriers.

Authors:  Elizabeth L Siegler; Yu Jeong Kim; Xianhui Chen; Natnaree Siriwon; John Mac; Jennifer A Rohrs; Paul D Bryson; Pin Wang
Journal:  Mol Ther       Date:  2017-08-19       Impact factor: 11.454

Review 3.  Advances in targeted therapy for malignant lymphoma.

Authors:  Li Wang; Wei Qin; Yu-Jia Huo; Xiao Li; Qing Shi; John E J Rasko; Anne Janin; Wei-Li Zhao
Journal:  Signal Transduct Target Ther       Date:  2020-03-06

4.  Dose intensification of TRAIL-inducing ONC201 inhibits metastasis and promotes intratumoral NK cell recruitment.

Authors:  Jessica Wagner; C Leah Kline; Lanlan Zhou; Kerry S Campbell; Alexander W MacFarlane; Anthony J Olszanski; Kathy Q Cai; Harvey H Hensley; Eric A Ross; Marie D Ralff; Andrew Zloza; Charles B Chesson; Jenna H Newman; Howard Kaufman; Joseph Bertino; Mark Stein; Wafik S El-Deiry
Journal:  J Clin Invest       Date:  2018-04-30       Impact factor: 14.808

5.  Cytotoxic and natural killer cell stimulatory constituents of Phyllanthus songboiensis.

Authors:  Yulin Ren; Chunhua Yuan; Youcai Deng; Ragu Kanagasabai; Tran Ngoc Ninh; Vuong Tan Tu; Hee-Byung Chai; Djaja D Soejarto; James R Fuchs; Jack C Yalowich; Jianhua Yu; A Douglas Kinghorn
Journal:  Phytochemistry       Date:  2015-01-14       Impact factor: 4.072

6.  Cancer Immunoediting in the Era of Immuno-oncology.

Authors:  Matthew M Gubin; Matthew D Vesely
Journal:  Clin Cancer Res       Date:  2022-09-15       Impact factor: 13.801

Review 7.  Advances in targeted therapy for malignant lymphoma.

Authors:  Li Wang; Wei Qin; Yu-Jia Huo; Xiao Li; Qing Shi; John E J Rasko; Anne Janin; Wei-Li Zhao
Journal:  Signal Transduct Target Ther       Date:  2020-03-06

8.  Association between interferon gamma 13-CA-repeats polymorphism and metastasis of nasopharyngeal carcinoma in a population of Northern China.

Authors:  Kaifei Hao; Zhaohui Yan; Yu Shuang; Jinsong Sun; Shudong Tao; Wenyuan Fu; Lei Liu
Journal:  Int J Clin Exp Pathol       Date:  2015-06-01

Review 9.  Next generation natural killer cells for cancer immunotherapy: the promise of genetic engineering.

Authors:  May Daher; Katayoun Rezvani
Journal:  Curr Opin Immunol       Date:  2018-03-30       Impact factor: 7.486

10.  siRNA against KIR3DL1 as a potential gene therapeutic agent in controlling HIV-1 infection.

Authors:  Geng-Feng Fu; Ji-Cheng Pan; Nan Lin; Hai-Yang Hu; Wei-Ming Tang; Jin-Shui Xu; Xiao-Liang Wang; Xiao-Qin Xu; Tao Qiu; Xiao-Yan Liu; Guo-Hong Chen; Tanmay Mahapatra; Xi-Ping Huan; Hai-Tao Yang
Journal:  Viral Immunol       Date:  2014-05-16       Impact factor: 2.257

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.